Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVP4YK)

Drug Name
CB1954 Drug Info
Synonyms
Tretazicar; CB 1954; 21919-05-1; CB1954; 5-(1-Aziridinyl)-2,4-dinitrobenzamide; 5-Aziridino-2,4-dinitrobenzamide; CB-1954; 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE; 5-Aziridinyl-2,4-dinitrobenzamide; Tretazicar [INN]; 2,4-Dinitroethyleneiminobenzamide; 2,4-Dinitro-5-ethyleneiminobenzamide; CHEMBL23330; CCRIS 1631; UNII-7865D5D01M; NSC 115829; 7865D5D01M; BRN 5825582; Benzamide,5-(1-aziridinyl)-2,4-dinitro-; Benzamide, 5-(1-aziridinyl)-2,4-dinitro-; CB1; C9H8N4O5; SMR000326847; aziridine dinitrobenzamide; CB1954(Tretazicar); AC1Q1YAR
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
89105
CAS Number
CAS 21919-05-1
TTD Drug ID
DMVP4YK
INTEDE Drug ID
DR1787

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Quinone reductase 2 (NQO2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Melatonin DMKWFBT Depression 6A70-6A7Z Approved [9]
NSC-645809 DMPJQZG Breast cancer 2C60-2C65 Phase 2 [10]
Prolarix DMZIQ8G Solid tumour/cancer 2A00-2F9Z Phase 2 [11]
Flavin-Adenine Dinucleotide DM5S4GK Discovery agent N.A. Investigative [2]
2-iodo-melatonin DMSEIUP Discovery agent N.A. Investigative [12]
3,4,5-Trimethoxy-4'-amino-trans-stilbene DMDBOJ5 Discovery agent N.A. Investigative [13]
NSC-645808 DMMBAR3 Discovery agent N.A. Investigative [10]
decynium 22 DMWCTZ7 Discovery agent N.A. Investigative [14]
NSC-106080 DMR6P9S Discovery agent N.A. Investigative [14]
NSC-99528 DMXZAIG Discovery agent N.A. Investigative [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Quinone reductase 1 (NQO1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [15]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [16]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [16]
Carboplatin DMG281S Adenocarcinoma 2D40 Approved [16]
Beta-Lapachone DMMI84K Solid tumour/cancer 2A00-2F9Z Phase 2 [17]
Nitrobenzanthrone DMN6L70 N. A. N. A. Investigative [18]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Metabolized By Oxygen-insensitive NADPH nitroreductase B (nfsB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nitrofurazone DMSM2KE Skin burns ME65.0 Approved [4]
Nitrazepam DMEGIQ6 Epilepsy 8A60-8A68 Approved [4]
Flunitrazepam DMGR5Z3 Insomnia 7A00-7A0Z Approved [19]
Clonazepam DMTO13J Absence epilepsy Approved [20]
Nitrobenzodiazepine DM254EW N. A. N. A. Investigative [19]
Misonidazole DMYB0HK N. A. N. A. Investigative [21]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Metabolized By Azoreductase (azoR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Balsalazide DM7I1T9 Inflammatory bowel disease DD72 Approved [22]
CTK0H-9987 DMSGYNP N. A. N. A. Phase 2 [23]
SC-47085 DMGH4Q0 N. A. N. A. Phase 2 [24]
Ipsalazide DMYEM59 N. A. N. A. Investigative [22]
Drug(s) Metabolized By Oxygen-insensitive NADPH nitroreductase A (nfsA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nitrofurazone DMSM2KE Skin burns ME65.0 Approved [25]
Nitrazepam DMEGIQ6 Epilepsy 8A60-8A68 Approved [25]
Loperamide DMOJZQ9 Diarrhea ME05.1 Approved [26]
HSDB-674 DMJG4WR N. A. N. A. Phase 1 [27]
Drug(s) Affected By NAD(P)H dehydrogenase 1 (NQO1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [28]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [29]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [30]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [31]
TECFIDERA DM2OVDT Multiple sclerosis 8A40 Approved [32]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [33]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [34]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [35]
Quercetin DM3NC4M Obesity 5B81 Approved [36]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Ribosyldihydronicotinamide dehydrogenase (NQO2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [38]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [39]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [40]
Tacrine DM51FY6 Alzheimer disease 8A20 Approved [8]
Panobinostat DM58WKG Chronic graft versus host disease Approved [41]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [42]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [43]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [44]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [45]
Hesperetin DMKER83 High blood cholesterol level 5C80.00 Approved [46]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Quinone reductase 2 (NQO2) TTJLP0R NQO2_HUMAN Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Quinone reductase 1 (NQO1) DENP5RY NQO1_HUMAN Substrate [3]
Oxygen-insensitive NADPH nitroreductase B (nfsB) DE0QLUZ NFSB_ECOLI Substrate [4] , [5]
Oxygen-insensitive NADPH nitroreductase A (nfsA) DEDPI65 NFSA_ECOLI Substrate [5]
N-ethylmaleimide reductase (nemA) DE1FR8H NEMA_ECOLI Substrate [5]
Azoreductase (azoR) DEEHWOG AZOR_ECOLI Substrate [5]
General stress protein 14 (ywrO) DE07EIQ GS14_BACSU Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Biotransformations [7]
Ribosyldihydronicotinamide dehydrogenase (NQO2) OTGDAJRZ NQO2_HUMAN Biotransformations [8]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019051)
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3 Gene Therapy of the Central Nervous System. Charter 22 - Prodrug-Activation Gene Therapy. 2006, Pages 291-301
4 Conversion of NfsB, a minor Escherichia coli nitroreductase, to a flavin reductase similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri, by a single amino acid substitution. J Bacteriol. 1996 Aug;178(15):4731-3.
5 Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochem Pharmacol. 2010 Mar 1;79(5):678-87.
6 Bacillus amyloliquefaciens orthologue of Bacillus subtilis ywrO encodes a nitroreductase enzyme which activates the prodrug CB 1954. Microbiology. 2002 Jan;148(Pt 1):297-306.
7 Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model. Arch Biochem Biophys. 2001 Jan 1;385(1):203-8. doi: 10.1006/abbi.2000.2144.
8 Reduction and scavenging of chemically reactive drug metabolites by NAD(P)H:quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 and variability in hepatic concentrations. Chem Res Toxicol. 2018 Feb 19;31(2):116-126.
9 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
10 Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
11 CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
12 Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
13 Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66.
14 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
15 Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
16 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
17 Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice. PLoS One. 2012;7(10):e47122.
18 Dose-dependent response to 3-nitrobenzanthrone exposure in human urothelial cancer cells. Chem Res Toxicol. 2017 Oct 16;30(10):1855-1864.
19 Structure-based development of bacterial nitroreductase against nitrobenzodiazepine-induced hypnosis. Biochem Pharmacol. 2012 Jun 15;83(12):1690-9.
20 Characterization of Escherichia coli nitroreductase NfsB in the metabolism of nitrobenzodiazepines. Biochem Pharmacol. 2009 Jul 1;78(1):96-103.
21 Metronidazole (flagyl) and misonidazole (Ro-07-0582): reduction by facultative anaerobes and cytotoxic action on hypoxic bacteria and mammalian cells in vivo. Br J Cancer Suppl. 1978 Jun;3:132-5.
22 Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983 Jul;28(7):609-15.
23 The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat. Xenobiotica. 1971 Mar;1(2):143-56.
24 Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs. 1991 Apr;41(4):647-64.
25 Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase. J Bacteriol. 1996 Aug;178(15):4508-14.
26 Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans. Drug Metab Dispos. 1995 Mar;23(3):354-62.
27 Absorption of (-)-nicotine-l-N-oxide in man and its reduction in the gastrointestinal tract. J Pharm Pharmacol. 1970 Sep;22(9):722-3.
28 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
29 Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol. 2018 Jan;92(1):371-381.
30 Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
31 Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
32 Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells. Anticancer Drugs. 2005 Feb;16(2):167-74.
33 Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer. 2000 Dec 15;88(6):873-80. doi: 10.1002/1097-0215(20001215)88:6<873::aid-ijc6>3.0.co;2-b.
34 Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
35 P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
36 Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin. Toxicol Lett. 2001 Feb 3;119(1):49-57.
37 Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
38 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
39 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
40 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
41 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
42 Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
43 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
44 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
45 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
46 Various concentrations of hesperetin induce different types of programmed cell death in human breast cancerous and normal cell lines in a ROS-dependent manner. Chem Biol Interact. 2023 Sep 1;382:110642. doi: 10.1016/j.cbi.2023.110642. Epub 2023 Jul 23.